VG Life Sciences (VGLS) Stock Overview

A biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. More details

VGLS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Latest financial reports are more than a year old

Does not have a meaningful market cap ($2M)

VGLS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

VG Life Sciences Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for VG Life Sciences
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	100.00%
3 Month Change	0%
1 Year Change	0%
3 Year Change	100.00%
5 Year Change	-97.92%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VGLS	US Biotechs	US Market
7D	0%	1.7%	1.3%
1Y	0%	27.1%	15.8%

Return vs Industry: VGLS underperformed the US Biotechs industry which returned 26.7% over the past year.

Return vs Market: VGLS underperformed the US Market which returned 14.6% over the past year.

Price Volatility

Is VGLS's price volatile compared to industry and market?
VGLS volatility
VGLS Average Weekly Movement	3,979.9%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.5%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: VGLS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VGLS's weekly volatility has decreased from 4951% to 3980% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1995	n/a	Haig Keledjian	www.vglifesciences.com

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers.

VG Life Sciences Inc. Fundamentals Summary

How do VG Life Sciences's earnings and revenue compare to its market cap?
VGLS fundamental statistics
Market cap	US$2.11m
Earnings (TTM)	-US$4.30m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is VGLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VGLS income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$4.30m
Earnings	-US$4.30m

Last Reported Earnings

Sep 30, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did VGLS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/25 06:18
End of Day Share Price	2025/12/19 00:00
Earnings	2015/09/30
Annual Earnings	2014/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VG Life Sciences Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kris Tuttle	SoundView Research